

---

## Hansa Biopharma - Improved use of IDEFIRIX

Hansa delivers a healthy increase in patients using IDEFIRIX. The impact on the valuation and the outlook is now related to the outlook for discounts and rebates, which are set to stabilize at a lower level going forward. In Q3, the total level of these provisions was approximately 43%. When adjusting for provisions actually relating to Q3, net sales would have been a very impressive SEK 64.6m and rebates of 7%. Our Base Case is SEK 125 (120) with an unchanged Bull Case of SEK 220 and a Bear Case of SEK 15.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Hansa Biopharma - Improved use of IDEFIRIX](#)